Hosted on MSN1mon
Roche's Elevidys shows sustained benefits in DMD study
Roche on Monday revealed positive results from the EMBARK trial, showing that its gene therapy Elevidys has sustained benefits for individuals with Duchenne muscular dystrophy (DMD) over a two ...
pharmaphorum4d
Sarepta bags key expansion to DMD gene therapy label in US
Elevidys (delandistrogene moxeparvovec) can now be used to treat both ambulatory and non-ambulatory boys aged four and above with DMD, a major expansion on its earlier accelerated approval with a ...
STAT24d
Duchenne gene therapy from Solid Biosciences produces promising results in early study
The data are the latest in a high-stakes race to create a better or safer gene therapy than Sarepta Therapeutics’ Elevidys, which was given broad approval last year amid intense debate at the ...
Nasdaq1mon
Sarepta Reports Positive Phase 3 EMBARK Data For Elevidys In Duchenne Muscular Dystrophy
(RTTNews) - Sarepta Therapeutics, Inc. (SRPT) Monday reported positive topline results from Part 2 of the Phase 3 study, dubbed EMBARK, of its gene therapy Elevidys approved for the treatment of ...
Business Insider1mon
Sarepta Therapeutics’ Strong Market Position and Elevidys’ Promising Prospects Drive Buy Rating
The recent data from Sarepta’s Elevidys Phase III trial demonstrated significant improvements in primary and functional endpoints, which establishes the treatment’s efficacy and safety.
Yahoo Finance24d
Solid says early data suggest ‘differentiated’ Duchenne gene therapy
Solid claims the results, while early, suggest SGT-003 could be more potent than Sarepta Therapeutics’ Elevidys, the only approved Duchenne gene therapy. The company intends to discuss an ...
Seeking Alpha9d
Sarepta Therapeutics' Long-Term Potential Intact Despite Near-Term Stock Weakness
Q4 2024 earnings showed 75% Y/Y revenue growth, driven by Elevidys, with net income tripling to $159.049 million and EPS of $1.50. Sarepta's pipeline includes gene therapies for LGMD, FSHD ...